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Introduction: Cachexia is a frequent feature of chronic diseases. This syndrome includes loss of 
body weight, depletion of skeletal muscle mass and altered metabolic homeostasis. Acceleration of 
protein and energy metabolism, impaired myogenesis and systemic inflammation contribute to 
cachexia. Its occurrence impinges on treatment tolerance as well as on patient quality of life, 
however, no effective therapy is still available. 
Areas covered in this review: This review will focus on the use of histone deacetylase inhibitors as 
pharmacological tools to prevent/delay cachexia, with particular reference to muscle wasting.    
Expert opinion: Besides their interference with histone acetylation, novel histone deacetylase 
inhibitors could be considered as exercise mimetics, supporting their use to treat muscle wasting-
associated diseases such as cachexia. In addition, the ability displayed by some of these inhibitors in 
modulating the release of extracellular vesicles from tumor cells might be an interesting tool to 
interfere with the development of cancer-induced muscle protein depletion. At present there are few 
clinical trials testing histone deacetylase inhibitors to treat cachexia, reflecting the lack of robust 
experimental evidence of effectiveness. Further investigation uncovering the pathogenic 
mechanisms of muscle wasting coupled with the identification of suitable histone deacetylase 
inhibitors targeting such alterations is needed. 
 
 






 Despite several potential therapeutic approaches for cachexia have been proposed on the 
basis of experimental studies, very few have been explored in clinical trials, rendering 
cachexia a still untreatable condition; 
 the balance between protein acetylation and deacetylation, mainly dependent on 
HAT/HDAC equilibrium, appears crucial in the regulation of muscle homeostasis in both 
physiology and pathology; 
 first generation HDAC inhibitors, characterized by broad action, can be ineffective to 
prevent/delay cachexia, or should be used at doses that can even become detrimental to the 
organism; 
 several studies suggest that HDAC inhibitors, being able to target specific mechanisms 
among which myogenesis and to behave as exercise mimetic agents, could be considered 
pharmacological tools suitable for preventing or at least delaying muscle wasting in chronic 
diseases; 
 novel HDAC inhibitors, more specific or endowed with additional activity could reveal 
useful to address at least some of the metabolic alterations occurring in cachexia and, in 
theory, might be included in combination treatment schedules. However, this hypothesis 
remains to be tested, since the number of clinical trials is still very low;   
 since the pathogenesis of cancer cachexia is multifactorial and no effective therapeutic 
strategies are actually available, a selectively tailored multidirectional approach to cachexia 







 Several chronic diseases are characterized by the occurrence of cachexia, a multi-organ 
syndrome that includes, among other features, loss of muscle and adipose tissue mass. Different 
factors contribute to the onset and progression of cachexia, such as reduced food intake, metabolic 
alterations and inflammation. The relative relevance of each factor may vary significantly, 
depending on the underlying chronic disease. 
 Perturbations occurring in the skeletal muscle appear particularly important in cachectic 
patients. Indeed, quality of life and tolerance to treatments are markedly impaired when muscle 
mass and function cannot be maintained at physiological levels, not to talk about the fact that 
muscle mass reduction below a certain threshold is not compatible with survival. Being the skeletal 
muscle the main body protein reservoir, changes in muscle size mainly reflect an altered regulation 
of protein turnover rates. In particular, muscle hypotrophy/atrophy can result from enhanced protein 
breakdown rates, reduced protein synthesis rates, or both [1]. The vast majority of the studies 
reported in the literature agree in considering the acceleration of protein degradation as the most 
relevant feature underlying muscle wasting in cachexia. Such catabolic drive depends on the 
activation above normal levels of three main intracellular proteolytic systems, namely Ca
2+
-
dependent proteolysis, ATP-ubiquitin-proteasome-dependent pathway and autophagic-lysosomal 
system. By contrast, data reported in the literature do not clearly show that protein synthesis is 
decreased in cachexia. As an example, in cancer patients either reduced or unchanged protein 
synthesis rates have been reported [2]. Of interest, the progression of cachexia from latent to 
refractory [3] is associated with an anabolic window that could be successfully exploited by 
nutritional interventions [4].    
 Reduced energy production and increased energy expenditure are frequently observed in 
patients with cachexia, that generally present with resting energy expenditure above the 
physiological level. Crucial in this regard are muscle mitochondria, that show both morphological 
and functional alterations, these latter being mainly characterized by mitochondrial uncoupling and 
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reduced oxidative capacity [5]. Impaired mitochondria lead to decreased production of ATP that 
translates into an energy deficit, eventually resulting in loss of muscle mass and strength. 
 The depletion of muscle mass occurring in chronic diseases is very frequently associated 
with systemic inflammation. In particular, the balance between pro- and anti-inflammatory 
cytokines is shifted in favor of the former. In this regard, increased TNFα and TNF soluble receptor 
in the blood have been reported in chronic heart failure or cancer patients
 
[6][7][8]. On the other 
side, genetic ablation of IL-10 in mice leads to loss of muscle mass
 
[9], and the activation of 
transcription factors such as NF-κB and STAT3, well known targets of pro-inflammatory 
mediators, has been shown to result in muscle atrophy[10][11], mainly in view of enhanced protein 
breakdown rates. However, also the anabolic side of muscle protein metabolism could be affected 
by inflammation. Indeed, TNFα has been shown to inhibit the signaling pathways dependent on 
insulin, IGF-1[3][12], myostatin [3][13] or bone morphogenetic proteins[14]. These latter in 
particular, belong to a sophisticated network of signals that regulate the activation of the 
transcription complex Smad1/5/8. The same study has also demonstrated that myostatin and BMP-
dependent pathways are alternatively activated, since both compete for Smad4. Inhibition of BMP 
signaling is able to revert muscle hypertrophy that characterizes mice lacking myostatin, suggesting 
that these signaling cascades are physiologically balanced to maintain muscle homeostasis [14]. 
Consistently, activation of BMP signaling in mice bearing the C26 colon carcinoma results in 
protection against muscle wasting (unpublished data). 
 Impaired myogenesis has also been proposed to contribute to muscle wasting, both in cancer 
cachexia and in aging-associated sarcopenia. Indeed, accumulation of Pax7
+
 myogenic precursors 
unable to form myotubes has been reported in the muscle of tumor-bearing mice [15][16], while a 
decline in muscle stem cell number and function occurs in sarcopenic muscles [17 and refs. 
therein]. 
 
2. Therapeutic strategies for cachexia: the state of the art 
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 So far, several therapeutic options have been proposed to treat cachexia, mainly deriving 
from both experimental and clinical studies. In view of the multifactorial pathogenesis of the 
syndrome, very different approaches have been described, including nutritional support, anti-
inflammatory drugs, orexigenic compounds, anabolic hormones, microbiota modifications and 
exercise.  
 The lack of adequate nutritional intake is a common finding in patients with heart failure, 
cancer, chronic obstructive pulmonary disease (COPD) and aging [1]. Along this line, nutritional 
interventions, better if personalized, will likely lead not just to improved patient nutritional status, 
but also to increased tolerance and response to treatments, finally resulting in good clinical 
outcome. This is particularly evident in cancer patients, where the adoption of a nutritional support 
regimen able to preserve patient body weight leads to increased tolerance to anti-cancer treatments, 
allowing to maintain the right dosage and timing [18]. However, despite the good results obtained 
with parenteral nutrition, there is clear-cut evidence that the enteral route should be preferred [1]. 
To this purpose, several studies have focused on agents able to stimulate appetite, such as 
glucocorticoids, amino acids, ghrelin analogues, or progestins (megestrol acetate)
 
[19]. These latter 
have been shown to improve anorexia by still unknown mechanisms likely including induction of 
neuropeptide Y, a factor that regulates appetite at the central level, and down-regulation of pro-
inflammatory cytokines. Along this line, progestins are widely used to treat cancer cachexia, alone 
or as component of multimodal approaches [20]. 
Another strategy to improve caloric intake relies on ghrelin. This is an orexigenic peptide 
that is also able to regulate energy metabolism and that has been proposed as an approach to treat 
cancer cachexia. In this regard, ghrelin administration to tumor-bearing animals results in improved 
food intake as well as body and muscle weight both in the presence and in the absence of 
chemotherapy [21]. These observations have led to design a number of clinical trial to test ghrelin 
effectiveness also in cancer patients. The most relevant ones are those investigating the effects of 
anamorelin, a ghrelin analogue. The results of these trials do not provide clear-cut evidence about 
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anamorelin effectiveness to treat cancer cachexia. Indeed, while positive results have been reported 
in non-small cell lung cancer patients, the ROMANA trials have shown that while anamorelin 
improves body weight loss and FAACT score in lung cancer patients, it is not able to rescue the loss 
of hand grip strength [22][23]. Subsequent investigations have shown that, in selected groups of 
patients, anamorelin also leads to improved performance status [24]. Other appetite stimulants such 
as macimorelin and a synthetic human ghrelin are actually under investigation [20]. 
 Taking into consideration the relevance of inflammation to the pathogenesis of cachexia, it 
is quite conceivable that a large number of studies have focused on anti-inflammatory drugs. Most 
of the work has been performed on experimental models, however clinical studies do exist. A 
randomized trial aimed to test the TNFα inhibitor thalidomide in pancreatic cancer patients with 
cachexia has proved effective in improving the loss of body weight and lean body mass. These 
results, however, has not been confirmed by a subsequent trial, while lenalidomide, a thalidomide 
analogue is currently under phase II investigation. The poor effectiveness of anti-TNFα strategies in 
preventing/delaying cancer cachexia also results from trials using monoclonal antibodies directed 
against this cytokine (infliximab). Other anti-inflammatory strategies involve the use of antibodies 
against IL-6, that have been reported to improve anemia and muscle wasting in pancreatic cancer 
patients. Of interest, targeting both TNFα and IL-6 with OHR118 has been shown to increase body 
weight and performance status in advanced cancer patients [20]. On the whole, the results show 
that, at least in the former settings, non-steroidal anti-inflammatory drugs or molecules able to 
directly interfere with cytokine bioactivity (specific antibodies, pentoxifylline, thalidomide) appear 
to positively impact on cachexia, even if it is unlikely that they can be used alone. Rather, their 
inclusion into combined therapeutic approaches to cachexia appears more concievable.  
 Several strategies have been proposed so far as a mean to counteract hypercatabolism and/or 
hypoanabolism. Along this line, approaches aimed at stimulating insulin, IGF-1 or androgen-
dependent signaling pathways, or based on supply of amino acids and their derivatives (glutamine,  
leucine, β-hydroxy-β-methylbutyrate), or involving β2-adrenergic agonists (clenbuterol, formoterol) 
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or myostatin antagonists, have been tested with promising results, at least in experimental settings
 
[19]. In this regard a phase II trial assessing the effects of a combination treatment regimen 
including formoterol and megestrol acetate in cancer patients with cachexia has shown improved 
muscle mass and function. These results, however, have been obtained studying a very small group 
of participants [20]. 
Non-steroidal selective androgen receptor modulators (SARMs) such as enobosarm have 
been proposed as a tool to improve anabolism. In phase II trials enobosarm has been reported to 
improve the loss of lean body mass, quality of life and performance status in patients affected by 
various types of tumors. Preliminary data from a phase III trial show increase in both lean body 
mass and muscle function [20]. 
 Treatments able to improve myogenesis have been proposed to valuably contribute to 
combination protocols aimed at counteracting the catabolic drive that characterizes muscle atrophy 
in cancer and aging. Indeed, tumor-bearing mice administered a MEK inhibitor show a reduced 
accumulation of myogenic (Pax7
+
) cells in the muscle, that is associated with improved muscle 
strength and mass [15][25]. Consistently, improved muscle trophism has been reported in 
cholangiocarcinoma patients treated with the MEK inhibitor selumetinib [26].  
 Another important line of intervention, mainly aimed to improve energy metabolism, is 
represented by strategies targeting mitochondria. In this regard, one of the most relevant is exercise. 
There are two types of training, namely resistance and endurance exercise, although pure protocols 
are almost nonexistent; the former enhances force production without impinging on mitochondrial 
function, while the latter induces metabolic adaptations by increasing the number of mitochondria 
and stimulating the shift from glycolytic to oxidative metabolism. 
 Despite many different approaches have been proposed to improve cachexia, this syndrome 
is still basically untreatable. One possible reason is that most of the interventions above impinge on 
a rather restricted spectrum, targeting specific pathways that do not necessarily cover the wide 
range of alterations that occur in cachexia. Just as an example, the pharmacological or genetic 
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inhibition of specific proteolytic systems does not improve cancer-induced muscle wasting [27][28]. 
Therefore, there is the possibility that approaches addressing cachexia from a more 'general' point of 
view could reveal useful. Particularly intriguing in this regard is the possibility to interfere with the 
epigenetic regulation of gene expression, that involves different pathways among which DNA 
methylation, nucleosome positioning and histone modifications. Since aberrant epigenetic 
regulation has been associated with several diseases, drugs able to act as epigenetic modifiers are 
actively searched. Among such drugs, histone deacteylase (HDAC) inhibitors are quite interesting, 
being able to improve both myogenesis and muscle phenotype in dystrophic mice [29]. 
 
3. HDACs in the skeletal muscle  
 Histone acetylation and deacetylation respectively result in increased or decreased cell 
transcriptional activity. Such balance mainly depends on the activity of two classes of enzymes, 
namely histone acetyltransferases (HATs) and HDACs [30].  In addition to histones, HDACs and 
HATs can also act on non-histone proteins. As an example, the cellular localization 
(activation/inactivation) of transcription factors such as Signal Transducer and Activator of 
Transcription 1 (STAT1), Nuclear Factor-κB (NF-κB), p53 and FOXO can be affected by 
acetylation of specific lysine residues. Not only, the acetylation state can modulate protein stability, 
for instance by inhibiting their ubiquitylation and subsequent degradation by the proteasome.
 Three groups of HATs [31] and 18 HDACs, organized into four classes (I-IV), have been 
described so far (Table 1), based on structure, function and phylogeny. Class I, II and IV HDACs 
are considered as 'classical' Zn
2+
-dependent HDACs, while class III HDACs (sirtuins; SIRT) use 
NAD+ as a cofactor. HDACs included into class I and class IV have a nuclear localization, class IIa 
HDACs mainly reside in the cytoplasm and class IIb HDACs can be found both in the nucleus and 
in the cytoplasm, shuttling between the two cell compartments. Class III HDACs can be found in 
both the nucleus and cytoplasm, but also in mitochondria [31][32].  
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 Class I HDACs are ubiquitous and have been found in many transcriptional corepressor 
complexes; their activity is mainly exerted by inhibiting transcription factors such as Sp1, p53 and 
the Rb protein. Class IIa and class IIb HDACs contribute to signal transduction pathways; 
phosphorylation causes in the former the exposure of a nuclear export sequence that allows the 
interaction with 14-3-3 proteins and the export to the cytoplasm. Class IIb HDAC6 and HDAC10 
have been reported to deacetylate tubulin and proteins involved in autophagy [28 and refs. therein]. 
SIRT have been shown to contribute to biological processes such as apoptosis, DNA repair and 
autophagy, but also to play a role in the regulation of lifespan, at least in lower eukaryotes
 
[33]. 
Consistently, aging, but also several chronic diseases, have been associated with altered SIRT 
activity [34]. HDAC11 has been discovered in 2002 and is the unique member of class IV HDACs. 
Its intracellular localization may vary in relation with cell type and environmental cues [35]. 
 HDACs, in particular HDACs 1, 4, 5, 6 and SIRT1, have been proposed to critically regulate 
the onset and progression of skeletal muscle atrophy. In this regard, HDAC2, HDAC4, HDAC6 and 
SIRT1 mRNA expression has been found increased in the skeletal muscle of animals exposed to 
nutrient deprivation, denervation or cast immobilization. The same study reports that only cast 
immobilization and denervation are associated with increased mRNA levels of HDAC1 and 
HDAC3. By contrast, decreased HDAC7 and HDAC9 levels have been observed [36]. These 
observations are in agreement with previous reports showing that HDAC4 and HDAC6 contribute 
to the regulation of skeletal muscle mass. Overexpression of the former, in particular, has been 
shown to result in reduced myofiber cross sectional area [37], while its ablation improves 
phenotype in denervated muscles [37][38].Similarly, HDAC6 is overexpressed during muscle 
atrophy and its inactivation has been shown to protect against denervation-induced muscle atrophy 
[39]. HDACs have also been proposed to play a role in the regulation of atrogene expression, such 
as the muscle-specific ubiquitin ligases MurF1 and atrogin1/MAFbx, acting on two transcription 
factors that are relevant to muscle atrophy, namely myogenin and FoxOs. Indeed, while acetylated 
FoxO3 is translocated from the nucleus to the cytoplasm and subsequently degraded, its 
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deacetylation results in increased transcriptional activity [40]. Another feed-forward mechanism 
also occurs, HDAC6 expression in atrophic muscles being regulated by FoxO3 [39]. Myogenin, one 
of the muscle regulatory factors overexpressed in late myogenesis, also participates to the induction 
of atrogin1/MAFbx during denervation, with a mechanism that requires HDAC4 [38]. Along the 
same line, reduced total HDAC activity and reduced HDAC2 and HDAC5 mRNA have been 
reported in macrophages of patients affected by COPD [41]. More recently, reduced HDAC2 
expression has been observed also in the muscle of COPD patients; such reduction finely correlates 
with muscle weakness [42]. 
 Among the SIRT family, SIRT1 is involved in the regulation of energy homeostasis, being 
able to stimulate cell survival, to enhance insulin production, and to improve carbohydrate 
metabolism, lipid homeostasis and mitochondrial mass and quality
 
[34]. Consistently, caloric 
restriction induces SIRT1 expression[34] and SIRT1 activity is enhanced by AMPK, a kinase that 
works as a cell energy sensor
 
[43]. SIRT1 genetic ablation in mice is associated with systemic 
inflammation and metabolic alterations[44]. By contrast, overexpression of SIRT1 reduces the 
metabolic impact of high fat diet
 
[45], partially inhibits the catabolic drive induced in the skeletal 
muscle by fasting or denervation
 
[46] and improves muscle phenotype in mdx mice[47]. Along the 
same line, SIRT activation in aged mice results in improved muscle metabolism, likely in view of 
the induction of the master regulator of mitochondrial biogenesis peroxisome proliferator-activated 
receptor gamma coactivator (PGC)1-α [31].  
 Finally, in several pathological states associated with muscle atrophy, HDACs have been 
shown to regulate and to be reciprocally regulated by microRNAs (miRs; [31]). As an example, 
decreased muscle-specific miR levels and increased class II HDACs have been shown in 






4. HDAC inhibitors  
 HDAC inhibitors regulate gene expression by modulating the binding to DNA of 
transcriptional activators/repressors. Several HDAC inhibitors, of both synthetic and natural origin, 
such as molecules isolated from bacteria (trichostatin A, FK322), vegetables or marine organisms, 
are actually available. On the basis of their chemical structure, these inhibitors can be classified into 
five different groups (Table 2; [49]). With the exception of sirtuin inhibitors, most of them interact 
with the HDAC Zn
2+
 domain through a zinc-binding group connected to a cap and target different 
HDAC classes (see above) or specific classes/isoforms. As an example, hydroxamic acid 
derivatives are rather non selective inhibitors, being active on both class I and class II HDACs, and 
displaying poor isoform specificity; nevertheless, they were the first type of HDAC inhibitors to 
obtain FDA approval. This class of inhibitors includes, among others, trichostatin A (TSA) and 
vorinostat, also known as SAHA (suberoylanilide hydroxamic acid). While the former has never 
been used in the clinical practice due to its toxicity and metabolic kinetic, SAHA was approved by 
FDA more than ten years ago as a treatment for T cell lymphoma. From SAHA entry among the 
accepted drugs, only other four molecules (belinostat, panobinostat, romidepsin and chidamide) 
received approval from regulatory agencies for the treatment of hematological tumors. Two of them 
(belinostat and panobinostats) belong to the same family of SAHA and TSA, while romidepsin, a 
cyclic peptide, and chidamide target class I HDACs. Along this line, several other HDAC inhibitors 
are currently under investigation in clinical trials for the treatment of various cancer types [49]. 
 Moreover, several pharmacological agents, some of them currently used in the clinical 
practice, have been reported to inhibit HDACs. As an example, valproic acid (VPA), a short chain 
fatty acid used for longer than five decades as mood-stabilizers and anti-epileptic drug, was 
discovered to inhibit both class I and II HDACs, the former more selectively than the latter. 
Similarly, HDAC inhibitory activity was reported for the 3-hydroxy-3-methyl-glutaryl-coenzyme A 
reductase inhibitor atorvastatin [50].  A detailed description of the different HDAC inhibitors 
actually available can be found in excellent recent reviews [49][50][51]. 
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 The research on HDAC inhibitors was initially developed to improve anti-cancer treatment, 
since low histone acetylation was frequently reported in cancer cells and interference with HDACs 
exerts anti-proliferative action and leads to cell death by apoptosis [52]. This latter effect is also 
dependent on the up-regulation of  pro-apoptotic molecules such as tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) and Death Receptor 5 (DR5), while pro-survival factors are 
down-regulated [53]. Moreover, HDAC inhibitors enhance the immune response against tumor by 
up-regulating the expression of both HLA and tumor-specific antigens as well as of and co-
stimulatory molecules [53][54].  While currently investigated mainly as anti-cancer drugs, HDAC 
inhibitors have been proposed as useful tools in a wide variety of pathologies, such as diabetes, 
heart failure, kidney disease and neurological disorders [50][51]. In this regard, several HDAC 
inhibitors were also studied in pre-clinical models of autoimmune diseases, showing reduced 
inflammation, mainly due to restoration of normal cytokine levels. HDAC inhibition was also 
reported to reactivate latent HIV, improving the effectiveness of antiviral therapies and resulting in 
depletion of HIV reservoir [55].  
 
5. Are HDAC inhibitors useful to counteract muscle wasting in cachexia? 
 Several lines of evidence suggest that HDAC inhibitors could be a pharmacological tool 
suitable for preventing or at least delaying muscle wasting in chronic diseases. Such an effect could 
be obtained targeting specific mechanisms, some of which will be addressed here below. 
 Interference with myostatin signaling 
 Myostatin,  a protein belonging to the TGFβ superfamily, is a negative regulator of muscle 
mass. Indeed, lack of myostatin and/or impaired myostatin-dependent signaling result in muscle 
hypertrophy, while myostatin overexpression/overactivation are a frequent finding in conditions 
associated with loss of muscle mass and function. Along this line, the inhibition of myostatin and/or 
ligands of the same family such as Activin A (see below), could be relevant as treatment options in 
diseases associated with muscle wasting [56]. 
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 Broad-spectrum HDAC inhibitors such as VPA, TSA, or sodium butyrate have been shown 
to down-regulate the signaling dependent on myostatin. In this regard, TSA has been shown to 
induce myostatin expression in C2C12 myotube cultures by modulating both ASK1-MKK3/6-p38 
MAPK and ASK1-MKK4-JNK signaling pathways [57].  In addition, muscle follistatin levels have 
been increased by treatment with HDAC inhibitors, resulting in down-regulation of myostatin 
activity and improved myoblast recruitment. Along this line, the dystrophic phenotype occurring in 
mdx mice has been improved by treatment with TSA. Such improvement is associated with 
increased follistatin expression and, likely, with inhibition of GSK-3β [58]. Consistently, both 
myostatin and follistatin levels are normalized in the muscle of tumor-bearing mice; however, such 
effect is not paralleled by improvement of muscle wasting [59]. 
 While TSA down-regulates myostatin levels, SAHA has been shown to induce the 
expression and release of Activin A, leading to R-SMAD phosphorylation, down-regulation of p21 
and inhibition of proliferation in melanoma cell lines [60]. Activin A shares the signal transduction 
pathway with myostatin, and its levels are frequently increased in cachexia [61]. In this regard, 
Activin A induction by SAHA would not be good, however, at present nobody has investigated if 
SAHA administration in conditions characterized by already high Activin A levels exerts the same 
effect.  
Myogenesis improvement 
 Treatment with TSA stimulates myoblast recruitment and fusion with existing myotubes, 
likely improving myogenesis [29] and improved myogenic differentiation in vitro has been recently 
reported using MS-275, a selective class I HDAC inhibitor, combined with a NO donor [62]. 
Consistently, in vitro HDAC inhibition by sodium butyrate appears to promote satellite cell fusion 
into existing myotubes as well as to stimulate myotube hypertrophy [29]. Damaged muscles  
exposed to TSA show increased expression of markers of myogenesis, supporting a beneficial effect 
of HDAC inhibitors on muscle regeneration [29]. More recently, tributyrin, a butyrate derivative, 
has been shown to positively impinge on muscle growth by stimulating satellite cell recruitment, 
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differentiation and fusion into myotubes in neonatal piglets, but not in adult animals [63]. In 
addition, HDAC inhibition in murine models of muscle dystrophy increases the ability of fibro-
adipogenic precursors to stimulate muscle stem cells [reviewed in 24]. 
  HDAC inhibitors have been proposed to target genes involved in myogenesis, however they 
can also impinge on non-histone proteins such as the transcription factors MEF2 and MyoD, further 
sustaining their acetylation occurring during myogenesis [29]. In addition, myoblasts exposed to 
HDAC inhibitors before differentiation show enhanced myogenin and Myf5 expression [29]. On the 
whole, these observations suggest that HDAC inhibitors  act on myogenesis at different levels, 
among which modulation of gene expression, acetylation level of muscle regulatory factors and 
follistatin availability. 
Effects on muscle mass and function 
 TSA administration protects against unloading-induced soleus  muscle wasting, mainly by 
preventing the increase of MuRF-1 expression [64]. The same inhibitor has been shown to result in 
increased survival and myofiber cross sectional area in transgenic mice modeling spinal muscular 
atrophy [65] and to improve both muscle atrophy and the alteration of the neuromuscular junction 
occurring in SOD1-G93A mice, an experimental model of amyotrophic lateral sclerosis (ALS). 
However, such protection has not been confirmed in ALS patients treated with valproic acid or 
phenylbutyrate [66] . This inconsistency could be due to the fact that the HDAC inhibitors used in 
the clinical studies have a rather poor selectivity, being able to inhibit most of the HDACs. Indeed, 
it is likely that specific HDACs participate to the onset and progression of ALS, while others might 
be required to maintain the homeostasis, and their inhibition could be detrimental. In this regard, a 
recent study has explored the effects of a new selective class II HDAC inhibitor, namely MC1568, 
on SOD1-G93A mice. The results show that MC1568 administration leads to improved motor 
activity, mainly associated with increased muscle electrical potential and expression of myogenic 
genes [67].  
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 Myofiber cross sectional area, muscle force and exercise capacity in mdx mice are markedly 
improved by HDAC inhibitors; such improvement is associated with reduced muscle degeneration 
and fibrosis [58][68]. Similar beneficial effects have been reported in an experimental model of 
limb girdle muscle dystrophy due to the lack of α-sarcoglycan [29]. 
  Experimental data show that butyrate administration improves sarcopenia of aging resulting 
in increased myofiber dimensions and reduced lipodystrophy. In addition, muscle energy 
metabolism is also improved, likely due to increased mitochondrial biogenesis and reduced 
oxidative stress [69].  
Modulating cachexia impinging on tumor growth 
 Many HDAC inhibitors, among which TSA, SAHA and the novel inhibitor chidamide, have 
been shown to inhibit cancer cell proliferation, alone or combined with chemotherapeutic drugs [52 
and refs. therein]. However, both TSA and VPA have proved unable to either impair in vivo tumor 
growth or improve cancer-induced muscle wasting in experimental murine models [59][71]. VPA, 
however, results in increased follistatin expression associated with reduced myostatin levels and 
SMAD2/3 phosphorylation [59]. In a subsequent study [72], improvement of experimental cancer 
cachexia has been reported using doses of VPA higher than those previously tested in [59] and [71]. 
The beneficial effects on muscle wasting reported by Sun et al. [72] have been ascribed to inhibition 
of C/EBPβ-regulated atrogin1/MAFbx expression. In agreement with the data reported above, 
administration of the novel HDAC inhibitor AR-42 to mice bearing the C26 tumor or the Lewis 
lung carcinoma (LLC) improves muscle wasting in the absence of decreased tumor burden [73]. A 
similar improvement of muscle mass depletion has also been reported in  a KP
fl/fl
C transgenic model 
of pancreatic cancer, however such protection appears associated with significant reduction of 
tumor mass [70].  
 Recently, different types of epigenetic modifiers have been shown to exert synergistic 
anticancer activity. Indeed, enhanced apoptosis has been reported in rhabdomyosarcoma or in 
urothelial carcinoma cells concomitantly treated with the pan-BET inhibitor JQ1 and with HDAC 
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inhibitors such as SAHA, quisinostat  or romidepsin [74][75]. These observations raise the 
possibility that the same combination could also be useful to improve cachexia. In this regard, 
recent observations show that treatment of mice bearing the C26 tumor with the BET inhibitor JQ1 
partially prevents body weight loss and muscle wasting, also improving animal survival time [76]. 
6. Conclusions 
Despite many promising results, there are still many challenges that limit the possibility to 
use HDAC inhibitors to treat cachexia. In this regard, most of the available data are obtained on 
experimental models and are mainly referred to the use of broad action HDAC inhibitors, while the 
number of clinical trials is still very low. Another important aspect is that the knowledge of the 
causative mechanisms of muscle wasting in cachexia is still far from being complete, limiting the 
rationale for the therapeutic use of HDAC inhibitors. In this regard, further research should clarify 
if specific HDAC isoforms are involved in cachexia and the mechanisms by which HDAC 
inhibitors may prevent the loss of muscle mass. The development of class-specific and isoform-
specific HDAC inhibitors will help to uncover the role of HDACs in muscle wasting of cachexia, 
potentially resulting in the generation of useful pharmacological tools.  
 
7. Expert Opinion 
 In the last years, novel HDAC inhibitors, endowed with increased selectivity and/or 
additional activity have been designed. As an example, a recent study reports the development of 
HDAC inhibitors able to donate acetyl groups, resembling the acetyl-donating property of aspirin. 
The biological activity of this new class of molecules has been tested on the tumor cell line MDA-
MB-231, showing an inhibition of cell proliferation [77]. However, mimicking the mechanism of 
action of aspirin, these agents could be used as double edged swords in order to address two specific 
alterations of cachexia: they could be able to impinge both locally, by modulating the myostatin 




 Another point relevant to the potential beneficial effect of HDAC inhibitors on muscle 
wasting of cachexia is the observation that such drugs might behave as exercise mimicking agents. 
Indeed, exercise has been proposed to activate anabolic pathways and to down-regulate the activity 
of pro-inflammatory cytokines, eventually improving the loss of muscle mass and strength [78]. In 
the last years, molecules able to partially mimic the effects of exercise, such as PPARδ or AMPK 
agonists, SIRT1 activators and the metabolic modulator trimetazidine [79] have been successfully 
investigated. In this regard, mice administered Scriptaid, a drug that does not inhibit HDAC 
activity, but that is able to disrupt the class IIa HDAC corepressor complex, show increased food 
intake associated with enhanced oxidative metabolism and insulin-stimulated glucose uptake in the 
skeletal muscle, closely resembling the metabolic effects exerted by the exercise mimicking agents 
reported above [80].  
 Last but not least, few lines of evidence indicate that tumor-derived extracellular vesicles are 
emerging as an important route of cell-to-cell communication. In this regard, few years ago miR21-
containing vesicles released by C26 colon cancer cells have been shown to mediate myoblast death, 
likely contributing to the onset of cancer-induced muscle wasting [81]. More recently, cachexia has 
been proposed to be mediated by tumors through the release of extracellular vesicles containing 
Hsp70/Hsp90 [82]. Along this line, the HDAC6 inhibitor tubacin specifically stimulates the release 
of CD133
+
 vesicles from CaCo2 colon cancer cells, increasing their susceptibility to anticancer 
treatments [83]. While there are no data available in the literature, the possibility that inhibiting 
HDACs could exert positive effect on muscle mass depletion that characterizes cancer cachexia also 
by modulating the amount and/or the content of tumor-derived extracellular vesicles cannot be 
discarded. 
 While the observations reported above suggest that HDAC inhibition could be a useful 
strategy to counteract muscle atrophy (Figure 1), a note of caution must be introduced, since a 
recent study reveals that long term inhibition of HDAC4 might be detrimental in conditions such as 
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aging or neuromuscular diseases, unless this is not coupled with other pharmacological 
interventions such as the adoption of antioxidant treatments [84]. 
 The rationale of using HDAC inhibitors in cachexia is to maintain the physiological level of 
gene transcription, preventing the overexpression of molecules that contribute to hypercatabolism, 
hypoanabolism, inflammation and impaired myogenesis. Along this line, it is likely that in order to 
be effective, HDAC inhibitors should be adopted as an early intervention, generating a sort of 
protective shield that renders chromatin not permissive to enhanced transcriptional activity. 
Consistently with this hypothesis, the positive effects induced in SOD1-G93A mice by MC1568 are 
lost in late disease stages [67]. 
 The results obtained testing HDAC inhibitors in experimental models of muscle wasting 
have led, so far, to only two registered clinical trials in the http://clinicaltrials.gov platform, one 
testing valproate and levocarnitine in children with spinal muscular atrophy (NCT01671384), 
having changes in muscle force as primary outcome, change in forced vital capacity and valproate 
side effects as secondary outcomes and the other administering sodium valproate for glycogen 
storage disease type V (NCT03112889), with changes in VO2 peak as primary outcome and 
presence of phosphorylase positive fibres, change in total walked distance (12 min walk), blood 
lactate and quality of life as secondary outcomes. Of these trials, the former appears still recruiting 
subjects, while the latter has been completed in February 2018 and not yet published. The limited 
translation of experimental results into clinical trials likely reflects the lack of solid evidences of 
HDAC inhibitor effectiveness in preventing/delaying the onset of cachexia.  
Further investigation uncovering the pathogenetic mechanisms of muscle wasting coupled with the 
identification of suitable HDAC inhibitors targeting such alterations (Figure 2) will potentially lead 
to new trials. If the results obtained in both experimental and clinical settings will be confirmed, 
HDAC inhibitors may become components of a multimodal preventative treatment for cachexia, in 
particular that frequently occurring in cancer patients. The pathogenesis of cancer cachexia is 
multifactorial, and no effective therapeutic strategies are actually available. In this regard, a 
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selectively tailored multidirectional approach to cachexia is gaining a growing consensus and could 
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Table 1. Classification of histone deacetylases (HDACs) in mammals 
Family Class Name Localization 





  HDAC8 Nucleus/cytoplasm 







Histone deacetylase Class IIb HDAC6 Cytoplasm 
    HDAC10 Cytoplasm 











  SIRT7 Nucleus 
Histone deacetylase Class IV HDAC11 Nucleus/cytoplasm 
SIRT = Sirtuin 
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Table 2. Structural classification of histone deacetylase (HDAC) inhibitors 
Class Examples 
sirtuin inhibitors nicotinamide 
 short chain fatty acids sodium butyrate, valproic acid 
 benzamides tubastatin A, entinostat 
 hydroxamic acid derivatives trichostatin A, vorinostat (SAHA) 
 cyclic peptides romidepsin 




Figure 1. HDAC potential targets in muscle wasting. The balance between histone acetyl 
transferase (HAT) and histone deacetylase (HDAC) activities contributes to the physiological rate 
of gene transcription. Cachexia is associated with wasting stimuli that alter the HAT/HDAC 
equilibrium, leading to overexpression and/or activation of transcription factors typically 
deregulated in cachexia, to impaired mitochondrial homeostasis and to defective myogenesis. These 




Figure 2. Molecular targets of specific HDAC inhibitors in cachexia. Distinct histone 
deacetylase (HDAC) inhibitors have been demonstrated to target several pathways/processes, 
potentially promoting muscle hypertrophy or counteracting muscle wasting. Given that specific 
HDAC inhibitors also exert anti-tumor activity, the simultaneous anabolic/anticatabolic action 
represents a desirable additional effect possibly allowing to treat both cancer and the development 
of cachexia with the same molecule.  
 
